Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANESH A ALAM

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1043227200
CMS profile
1133215
Location
WINFIELD, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,068.69

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $939.26 3
Food and Beverage $129.43 5

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $1,049.86 7
Otsuka America Pharmaceutical, Inc. $18.83 1

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANESH A ALAM

NPI 1043227200 · CMS profile ID 1133215

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

WINFIELD, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043227200?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043227200?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043227200?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1043227200?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $1,068.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $15.7211/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014616 CMS
Janssen Pharmaceuticals, Inc $47.4911/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014620 CMS
Janssen Pharmaceuticals, Inc $15.7311/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014624 CMS
Janssen Pharmaceuticals, Inc $31.6611/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014632 CMS
Janssen Pharmaceuticals, Inc $277.8411/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014606 CMS
Janssen Pharmaceuticals, Inc $164.3311/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014610 CMS
Janssen Pharmaceuticals, Inc $497.0911/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014638 CMS
Otsuka America Pharmaceutical, Inc. $18.8308/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118850406 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,495.83 24
PY2020 $2,250.00 4
PY2024 $1,068.69 8
PY2025 $16,767.00 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,292.36 12
PY2025 Principal investigator $131,175.91 17
PY2024 Principal investigator $333,688.72 94
PY2023 Principal investigator $642,167.72 100
PY2022 Principal investigator $346,465.71 57
PY2021 Principal investigator $149,586.53 50
PY2020 Principal investigator $478,016.95 67
PY2019 Recipient $1,282.88 8
PY2019 Principal investigator $534,507.18 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,250.00 10/25/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143139702
Principal investigator 1 Indivior Inc. $1,000.00 10/08/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144118360
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,614.71 10/04/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143137800
Principal investigator 1 Alkermes, Inc. $10,500.00 08/02/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder No dispute reported 06/30/2026 1084812596
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,773.38 08/02/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143127829
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $13,067.04 07/05/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143127273
Principal investigator 1 ACADIA Pharmaceuticals Inc $9,198.00 07/03/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE LLC
ACP-204-006 No dispute reported 06/30/2026 1138421712
Principal investigator 1 Indivior Inc. $323.76 06/20/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116867
Principal investigator 1 Indivior Inc. $246.08 06/20/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116869
Principal investigator 1 Indivior Inc. $284.00 06/20/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116871
Principal investigator 1 Indivior Inc. $7,095.82 06/11/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116845
Principal investigator 1 ACADIA Pharmaceuticals Inc $6,308.00 06/07/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE LLC
ACP-204-006 No dispute reported 06/30/2026 1138421341
Principal investigator 1 ACADIA Pharmaceuticals Inc $6,308.00 06/07/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE LLC
ACP-204-006 No dispute reported 06/30/2026 1138421345
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $11,690.55 05/30/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143126514
Principal investigator 1 Indivior Inc. $157.92 05/28/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116825
Principal investigator 1 Indivior Inc. $36.00 05/28/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116827
Principal investigator 1 Indivior Inc. $141.92 05/21/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116781
Principal investigator 1 Janssen Research & Development, LLC $210.00 05/17/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079017952
Principal investigator 1 Janssen Research & Development, LLC $176.00 05/16/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079017958
Principal investigator 1 Indivior Inc. $157.92 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116529
Principal investigator 1 Indivior Inc. $405.92 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116533
Principal investigator 1 Indivior Inc. $238.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116535
Principal investigator 1 Indivior Inc. $653.92 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116537
Principal investigator 1 Indivior Inc. $339.36 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116539
Principal investigator 1 Indivior Inc. $71.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116541
Principal investigator 1 Indivior Inc. $405.96 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116543
Principal investigator 1 Indivior Inc. $727.68 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116545
Principal investigator 1 Indivior Inc. $2,078.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116547
Principal investigator 1 Indivior Inc. $92.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116549
Principal investigator 1 Indivior Inc. $358.40 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116551
Principal investigator 1 Indivior Inc. $588.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116555
Principal investigator 1 Indivior Inc. $165.84 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116557
Principal investigator 1 Indivior Inc. $84.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116559
Principal investigator 1 Indivior Inc. $84.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116561
Principal investigator 1 Indivior Inc. $65.84 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116563
Principal investigator 1 Indivior Inc. $588.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116565
Principal investigator 1 Indivior Inc. $310.88 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116567
Principal investigator 1 Indivior Inc. $107.92 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116569
Principal investigator 1 Indivior Inc. $462.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116571
Principal investigator 1 Indivior Inc. $3,400.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116573
Principal investigator 1 Indivior Inc. $157.92 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116577
Principal investigator 1 Indivior Inc. $310.88 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116579
Principal investigator 1 Indivior Inc. $294.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116581
Principal investigator 1 Indivior Inc. $157.92 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116583
Principal investigator 1 Indivior Inc. $142.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116585
Principal investigator 1 Indivior Inc. $107.92 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116587
Principal investigator 1 Indivior Inc. $107.92 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116589
Principal investigator 1 Indivior Inc. $42.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116591
Principal investigator 1 Indivior Inc. $2,078.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116593
Principal investigator 1 Indivior Inc. $50.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116595
Principal investigator 1 Indivior Inc. $252.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116599
Principal investigator 1 Indivior Inc. $157.92 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116601
Principal investigator 1 Indivior Inc. $310.88 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116603
Principal investigator 1 Indivior Inc. $228.92 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116605
Principal investigator 1 Indivior Inc. $260.88 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116607
Principal investigator 1 Indivior Inc. $157.92 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116609
Principal investigator 1 Indivior Inc. $100.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116611
Principal investigator 1 Indivior Inc. $126.00 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116613
Principal investigator 1 Indivior Inc. $7.92 05/14/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116615
Principal investigator 1 Janssen Research & Development, LLC $550.00 05/06/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079017948
Principal investigator 1 Janssen Research & Development, LLC $462.00 05/06/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079017964
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $375.00 05/03/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143125991
Principal investigator 1 Indivior Inc. $5,000.00 05/02/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116497
Principal investigator 1 Indivior Inc. $8,000.00 05/02/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116499
Principal investigator 1 Indivior Inc. $1,950.00 05/02/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116501
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $31,766.00 04/30/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6 DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1118845818
Principal investigator 1 Janssen Research & Development, LLC $316.00 04/29/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079017946
Principal investigator 1 Janssen Research & Development, LLC $18,824.00 04/29/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079017954
Principal investigator 1 Janssen Research & Development, LLC $53.00 04/29/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079017962
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $19,248.00 04/26/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143125827
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $19,315.29 04/26/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143125831
Principal investigator 1 Indivior Inc. $1,182.00 04/23/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116307
Principal investigator 1 Janssen Research & Development, LLC $258.00 04/22/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079017956
Principal investigator 1 Indivior Inc. $1,182.00 04/16/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116285
Principal investigator 1 Indivior Inc. $1,322.00 04/12/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116257
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $25,753.69 04/05/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143125190
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $16,485.46 04/05/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143125194
Principal investigator 1 Indivior Inc. $1,322.00 04/04/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116213
Principal investigator 1 Indivior Inc. $930.00 03/26/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116159
Principal investigator 1 Indivior Inc. $930.00 03/19/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116007
Principal investigator 1 Janssen Research & Development, LLC $2,210.00 03/18/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079017950
Principal investigator 1 Indivior Inc. $1,322.00 03/12/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115977
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $39,036.78 03/01/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143124432
Principal investigator 1 Indivior Inc. $1,322.00 02/29/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115907
Principal investigator 1 Indivior Inc. $930.00 02/21/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115871
Principal investigator 1 Indivior Inc. $930.00 02/13/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115745
Principal investigator 1 Janssen Research & Development, LLC $14,166.00 02/08/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079017960
Principal investigator 1 Indivior Inc. $1,322.00 02/07/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115705
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,375.41 01/26/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143123924
Principal investigator 1 Indivior Inc. $613.70 01/18/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115557
Principal investigator 1 Indivior Inc. $2,644.00 01/16/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115533
Principal investigator 1 Indivior Inc. $3,560.00 01/09/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115481
Principal investigator 1 Novartis Pharmaceuticals Corporation $333.57 01/09/2024 Non-covered Recipient Entity
NEUROPSYCH CENTER OF PALM BEACHES
A Double-blind, Placebo-controlled, Randomized Dose-ranging Trial to Investigate Efficacy and Safety of Intravenous MIJ821 Infusion in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent No dispute reported 06/30/2026 1089690175
Principal investigator 1 Indivior Inc. $2,882.00 01/05/2024 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115435